PSA markers in prostate cancer detection (Q35609528)

9 August 2017

1 reference

title

PSA markers in prostate cancer detection (English)

1 reference

9 August 2017

1 reference

2

Alan W Partin

1 reference

9 August 2017

Matthew B Gretzer

1

1 reference

9 August 2017

publication date

1 November 2003

1 reference

Urologic Clinics of North America

9 August 2017

published in

1 reference

9 August 2017

volume

30

1 reference

9 August 2017

issue

4

1 reference

9 August 2017

page(s)

677-686

1 reference

Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

1 reference

7 January 2021

Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

A guide to the interpretation of serum prostate specific antigen levels

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Prostate-specific antigen: critical issues for the practicing physician

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Prevalence and Pathological Extent of Prostate Cancer in Men with Prostate Specific Antigen Levels of 2.9 to 4.0 NG./ML

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Prostate specific antigen density in patients with histologically proven prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Serum Prostate Specific Antigen Complexed toα1-Antichymotrypsin as an Indicator of Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Prostate-specific antigen and lack of specificity for prostate cells

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

NONPROSTATIC SOURCES OF PROSTATE-SPECIFIC ANTIGEN

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Original Articles: Prostate Cancer: Measurement of Serum Prostate Specific Antigen Levels in Women and in Prostatectomized Men With an Ultrasensitive Immunoassay Technique

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Prostate-Specific antigen expression by various tumors

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves.

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Diagnosis of Prostatic Carcinoma: The Yield of Serum Prostate Specific Antigen, Digital Rectal Examination and Transrectal Ultrasonography

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging.

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era.

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer.

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

An artificial neural network considerably improves the diagnostic power of percent free prostate-specific antigen in prostate cancer diagnosis: results of a 5-year investigation.

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when?

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of two different test populations

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Significance of free to total PSA ratio in men with slightly elevated serum PSA levels: a cooperative study

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

The clinical usefulness of percent free-PSA

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Rapid Exponential Elimination of Free Prostate-Specific Antigen Contrasts the Slow, Capacity-Limited Elimination of PSA Complexed to Alpha1-Antichymotrypsin From Serum

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

A comparison of three free and total PSA assays

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Re: Editorial: Can Prostate Specific Antigen Derivatives Reduce the Frequency of Unnecessary Prostate Biopsies?

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

The necessity of a second prostate biopsy cannot be predicted by PSA or PSA derivatives (density or free:total ratio) in men with prior negative prostatic biopsies

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Biology of prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

"BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Free prostate-specific antigen in serum is becoming more complex

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen-induced LNCaP cells

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Clinical Evaluation of Serum Prostate‐Specific Antigen‐Alpha1 ‐ Antichymotrypsin Complex Values in Diagnosis of Prostate Cancer: A Cooperative Study

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Development of an immunoassay specific for the PSA-ACT complex without the problem of high background

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Bayer immuno 1™ PSA assay: An automated, ultrasensitive method to quantitate total PSA in serum

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Complexed prostate-specific antigen and its volume indexes in the detection of prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL.

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prost

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(03)50057-0

7 January 2021

10.1016/S0094-0143(03)00057-0

Identifiers

DOI

1 reference

release_zh5la4ufr5f3zk4mcm4m3lrs74

9 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zh5la4ufr5f3zk4mcm4m3lrs74

24 November 2022

mapped directly with Wikidata item

1 reference